Ravi Salgia to Protein-Tyrosine Kinases
This is a "connection" page, showing publications Ravi Salgia has written about Protein-Tyrosine Kinases.
Connection Strength
3.296
-
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
Score: 0.638
-
ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. J Clin Neurosci. 2015 Dec; 22(12):1978-9.
Score: 0.471
-
Non-receptor tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem. 2007 Nov; 7(6):633-42.
Score: 0.276
-
Tyrosine kinase mutations in human cancer. Curr Mol Med. 2007 Feb; 7(1):77-84.
Score: 0.262
-
Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases. Methods Mol Med. 2003; 85:87-105.
Score: 0.198
-
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000 Jul 20; 19(31):3521-8.
Score: 0.167
-
Role of focal adhesion proteins in signal transduction and oncogenesis. Crit Rev Oncog. 1997; 8(4):343-58.
Score: 0.130
-
The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem. 1996 Dec 06; 271(49):31222-6.
Score: 0.130
-
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20; 371(21):1963-71.
Score: 0.112
-
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
Score: 0.088
-
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6.
Score: 0.086
-
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 2011 Feb; 25(2):281-9.
Score: 0.085
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
Score: 0.085
-
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology. 2006 Nov; 11(6):687-92.
Score: 0.064
-
Biology and novel therapeutics for neuroendocrine tumors of the lung. J Biol Regul Homeost Agents. 2004 Jul-Dec; 18(3-4):275-90.
Score: 0.055
-
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer. J Environ Pathol Toxicol Oncol. 2004; 23(4):237-51.
Score: 0.053
-
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. J Cell Mol Med. 2003 Apr-Jun; 7(2):157-64.
Score: 0.050
-
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000 Aug 11; 275(32):24273-8.
Score: 0.042
-
The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem. 1999 Dec 17; 274(51):36684-92.
Score: 0.040
-
The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. J Biol Chem. 1997 Dec 26; 272(52):33373-6.
Score: 0.035
-
BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997 Jul 01; 100(1):46-57.
Score: 0.034
-
Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene. 1995 Sep 21; 11(6):1149-55.
Score: 0.030
-
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995 Aug; 23(9):1040-8.
Score: 0.030
-
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem. 1995 Mar 10; 270(10):5039-47.
Score: 0.029
-
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem. 1994 Feb 18; 269(7):5016-21.
Score: 0.027
-
Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S52-60.
Score: 0.016
-
Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1. Ann Thorac Surg. 2004 Aug; 78(2):450-7.
Score: 0.014
-
Targeted molecules in small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):106-11.
Score: 0.013
-
A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. J Biol Chem. 2002 Jun 07; 277(23):20887-94.
Score: 0.012
-
SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J Biol Chem. 2001 Jan 26; 276(4):2451-8.
Score: 0.011
-
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996 Feb 15; 12(4):839-46.
Score: 0.008
-
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993 Oct; 21(11):1460-6.
Score: 0.007